Portal de investigación
Prognostic significance of molecular classification in high-risk endometrial cancer patients undergoing sentinel lymph node mapping
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Mariano L.O.
- Berta D.-F.
- Octavio A.S.
- Fernando R.R.
- María de los Reyes O.P.
- Nisa B.A.
- Sergi F.G.
- Alberto Rafael G.C.
- Josefa M.-S.
- Soledad F.
- Joana A.V.
- Kristina A.
- Ignacio A.-C.
- Paula A.
- Sara I.
Grupos
Abstract
Introduction: The adoption of selective sentinel lymph node biopsy (SLNB) as a viable alternative to lymphadenectomy, along with the redefinition of nodal risk groups based on molecular classification, has significantly changed the management of early-stage, high-risk preoperative endometrial cancer. Materials and methods: A retrospective, multicenter study was conducted under the auspices of the Spanish Gynecologic Oncology Group to evaluate recurrence rates and oncologic outcomes in patients stratified by molecular risk. Three groups were compared: SLNB alone (G1), SLNB combined with pelvic and/or para-aortic lymphadenectomy (G2), and pelvic and/or para-aortic lymphadenectomy without SLNB (G3). The primary endpoint was recurrence rate; secondary endpoints included disease-free survival (DFS), overall survival (OS), recurrence patterns. Results: A total of 221 patients from 14 centers were included, with a median follow-up of 24.4 months (IQR 17–42). Forty-four patients (19.9 %) experienced recurrence. Relapse rates were 15.4 % in G1, 15.8 % in G2, and 22.2 % in G3 (p = 0.479). DFS rates were 84.6 % in G1, 84.1 % in G2, and 77.8 % in G3 (p = 0.56). OS rates were 94.2 %, 90.9 %, and 92.6 %, respectively (p = 0.651). Among the 44 patients with documented recurrence, seven had nodal recurrences, with only two occurring in the group managed with SLNB alone. Conclusion: In this study, patients with early-stage, high-risk preoperative endometrial cancer—classified by molecular subgroups—showed no significant differences in relapse rates, disease-free survival, or overall survival across the three management strategies. Further prospective studies with longer follow-up are warranted to validate these preliminary findings. © 2025 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology
Datos de la publicación
- ISSN/ISSNe:
- 0748-7983, 1532-2157
- Tipo:
- Article
- Páginas:
- -
- PubMed:
- 40834694
- Enlace a otro recurso:
- www.scopus.com
- Factor de Impacto:
- 1,016 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
EJSO ELSEVIER SCI LTD
Documentos
- No hay documentos
Filiaciones
Keywords
- Aged; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Sentinel Lymph Node; Sentinel Lymph Node Biopsy; Survival Rate; aged; Article; cancer prognosis; cancer recurrence; cancer survival; clinical outcome; controlled study; disease free survival; endometrium carcinoma; female; follow up; high risk patient; human; major clinical study; multicenter study; overall survival; para-aortic lymphadenectomy; pelvis lymphadenectomy; peroperative complication; postoperative complication; recurrence risk; retrospective study; sentinel lymph node biopsy; cancer staging; clinical trial; endometrium tumor; epidemiology; genetics; lymph node dissection; lymph node metastasis; middle aged; pathology; prognosis; sentinel lymph node; surgery; survival rate; tumor recurrence
Cita
Mariano LO,PABLO P-I,Berta D-F,Octavio AS,Fernando RR,María de los Reyes OP,Nisa BA,Sergi FG,Alberto GC,Josefa M-S,Soledad F,Joana AV,Kristina A,Ignacio A-C,Paula A,Sara I. Prognostic significance of molecular classification in high-risk endometrial cancer patients undergoing sentinel lymph node mapping. EJSO. 2025. 51. (10):110385. IF:3,500. (1).